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The Power and Limitations of 
Pharmacogenetic Epidemiology
Kate Lapane1 and Martin A. Weinstock1,2
Ovid and many physicians in the thousands of years since have been stymied 
by the large interindividual variability in drug response and toxicity. That all 
patients do not reap the same benefits from the same drugs is well estab-
lished. In the case of statins, estimates of effectiveness range from 30 to 70% 
of users (Spear et al., 2001). Disentangling why this occurs is complex, and two 
new disciplines are likely to make headway in furthering our understanding of 
these phenomena.
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"Medicine sometimes snatches 
away health, sometimes gives it."
Ovid
Pharmacogenetics (single-gene focus) 
and pharmacogenomics (focus on 
the entire spectrum of genes) seek to 
understand variability in genes encod-
ing drug-metabolizing enzymes, drug 
receptors, and proteins involved in 
pathway signaling. Patel et al. (2007) 
evaluate the hypothesis that a common 
genetic variant in the steroid receptor 
(NR3C1) gene increases corticosteroid 
sensitivity, thus modifying the effect of 
glucocorticoid use on the risk of squa-
mous cell carcinoma. This relationship 
is clearly demonstrated in Figure 1 in 
that article, which shows that the rela-
tive risk estimate for squamous cell car-
cinoma is more than doubled among 
glucocorticoid users with the genetic 
variant relative to glucocorticoid users 
without the variant. The study provides 
the opportunity to reflect on the power 
and limitations of non-experimental 
pharmacoepidemiologic studies, as 
well as the potential clinical utility of 
pharmacogenetic knowledge.
The clinical decision-making pro-
cess requires evidence of effectiveness 
from clinical trials and evidence from 
non-experimental epidemiologic stud-
ies. Although considered the paradigm 
of research, trials are limited in their 
ability to identify potential adverse 
drug effects owing to their relatively 
small size and short duration. In tri-
als, adverse events with long latency 
periods, such as many cancers, are 
unlikely to be detected. Trials are often 
not sufficiently powered to detect drug 
effects that occur infrequently. In a 
trial of 3,000 patients, events occur-
ring in fewer than 1 in 1,000 patients 
cannot be reliably detected. In a trial 
of 500 patients, events occurring in 
fewer than 1 in 166 patients cannot 
be detected. The shortcomings of the 
knowledge generated by trials can be 
complemented by evidence from non-
experimental epidemiologic studies. 
Specifically, well-designed case–con-
trol designs provide an efficient meth-
od for identifying risks associated with 
drug use when the disease is rare or 
the latency period long. In contrast to 
cohort studies (in which investigators 
sample populations on the basis of drug 
exposure and determine incidence of 
disease), case–control studies require 
that the investigators sample on disease 
status—typically identifying people 
with the disease of interest (cases) and 
sampling a fraction of the person-time 
experience from which the cases came 
(controls). For example, the squamous 
cell carcinoma case–control study by 
Patel et al. (2007) included 607 par-
ticipants. The incidence of squamous 
cell carcinoma in the population from 
which their sample was derived was 97 
and 32 per 100,000 per year in men 
and women. Using a cohort design, 
the investigators would have needed 
to include at least 17 times as many 
participants to detect an effect size of 
5 with sufficient statistical power, or at 
least 93,000 people (4 non-users for 
each glucocorticoid user), to detect a 
more modest effect size of 2. An effi-
cient study design evaluates the same 
hypothesis with equal precision but 
requires far fewer study participants.
Although non-experimental studies 
provide useful information for clinical 
practice, several limitations of these 
designs must be mentioned. First, only 
the randomized trial can effectively 
control for distortion in the measure 
of effect due to unmeasured factors. 
In non-experimental studies of drug 
effects, one can never completely rule 
out this non-causal explanation for the 
findings. Second, data-mining activities 
can produce false-positive study find-
ings. As such, epidemiologic studies 
should be strongly rooted from a priori 
hypotheses to be tested using appro-
priate designs. The article by Patel et 
al. (2007) cites a priori evidence of 
the importance of a polymorphism in 
the NR3C1 gene for steroid hyperre-
sponsiveness (although we are not told 
whether other polymorphisms or other 
genes were tested). Of concern in 
many pharmacogenomics studies is the 
large number of genes being evaluated, 
which increases the probability of a 
type II error—falsely claiming an asso-
ciation given that the truth is there is no 
association. Appropriate adjustments 
for the multiple statistical comparisons 
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must be made to appropriately con-
sider the evidence generated from such 
studies. A q value, which quantifies the 
false discovery rate, may be used in this 
context. For example, a q value of 0.01 
indicates that when subsetting signifi-
cant genes from all genes, 1% of the 
selected genes would be expected to 
have a false-positive association with 
the outcome. Although such informa-
tion helps put the evidence into con-
text, pharmacogenetic research is also 
subject to publication bias (Colhoun 
et al., 2003). Studies finding no asso-
ciations between genetic makeup and 
disease outcomes may be less likely 
to be published than studies that dem-
onstrate statistically significant rela-
tionships. If Patel et al. (2007) found 
no statistically significant association 
between the steroid receptor polymor-
phism and squamous cell carcinoma, 
their report might not have been pub-
lished or it might have been published 
in a less prominent setting.
Despite the limitations of the 
research, pharmacoepidemiologic 
studies providing pharmacogenetic/
genomic evidence can provide fine-
tuned information regarding risks and 
benefits of treatments given an indi-
vidual’s genetic profile. The ability to 
predict likely nonresponse to treatment 
may lead to the avoidance of needless 
drug toxicity and expense. For example, 
trastuzumab is effective only in patients 
with  human epidermal growth factor 
receptor protein overexpression (HER)-
2 tumors.  Given that only ~15–30% 
have HER-2 tumors and the expense of 
trastuzumab (~$3,000 per month), the 
clinical and financial benefits of genet-
ic profiling are considerable. Further, 
the ability to predict individuals likely 
to experience toxic effects of drug treat-
ments can be an important addition to 
clinical practice and in some cases has 
redefined the standard of care, such as 
the routine identification of patients 
who have no thiopurint-S-methyltrans-
ferase (TPMT) activity. In these patients, 
a normal dose of purine drugs results 
in an accumulation of the active com-
pound, placing the patient at increased 
risk for the myelosuppressive effects 
of mercaptopurine. The clinical solu-
tion is a substantial dose reduction 
(~10–15%). Whereas only 1 in 300 
patients may have TPMT deficiency, 
the adverse effect is so severe and the 
clinical solution so easy that integrating 
genetic profiling in this case is warrant-
ed. Another recent example is the anti-
psychotic agent thioridazine. The drug 
label for thioridazine indicates that its 
use is contraindicated in people with 
a genetic defect leading to reduced 
levels of activity of P450 2D6 (~7% of 
the general population), because of the 
increased risk of serious, potentially 
fatal cardiac arrhythmias. The extent to 
which genetic profiling is being inte-
grated into clinical use of this drug has 
yet to be evaluated.
Another potential application of 
increased understanding of the relation 
between genetic profiles and adverse 
effects of drugs may be to reintroduce 
drugs withdrawn from the market due 
to adverse effects (some 38 drugs over 
the past 16 years). Proposed criteria for 
considering the reintroduction include 
the following: (i) the drug was highly 
efficacious compared with alternatives, 
(ii) the mechanism of toxicity was well 
understood, (iii) there were no obvi-
ous nongenetic risk factors in a major-
ity of patients with adverse effects, and 
(iv) the locus of potential pharmacoge-
netic defect is understood (Shar, 2006). 
When these criteria are applied, only 
one drug, perhexiline (withdrawn in 
1988), may be suitable for genotype-
based prescribing (Shar, 2006).
Although patients may be likely 
to support personalized medicine, a 
recent review pointed to the role of 
regulation and reimbursement issues 
among the major drivers of diffu-
sion of technology (Phillips, 2006). 
Indeed, the FDA mandates that drug 
labeling shall describe the available 
evidence and identify specific tests 
“necessary for selection or monitoring 
of the patients who need the drug” if 
evidence is available to support safety 
and effectiveness in selected subpopu-
lations (Food and Drug Administration, 
2006). The agency recommends that 
sponsors of new drugs voluntarily 
explore the impact of genetic varia-
tions on pharmacokinetics, pharmaco-
dynamics, and dose–response relation-
ships. Pharmacogenomic information 
is contained in about 10% of labels for 
drugs recently approved by the FDA. 
Yet the lack of actual predictive power 
of new molecular markers hampers 
progress in implementing individual-
ized medicine (Garrison and Austin, 
2006). Genetic tests must be both sen-
sitive and specific for the variant(s) to 
have clinical utility.
We will certainly see more investi-
gations in pharmacogenetic epidemiol-
ogy like that of Patel et al. (2007), and 
we expect the insights from them to 
feed back into the laboratory to facili-
tate development of chemopreventive 
and therapeutic innovations, as well 
as into clinical epidemiology to deter-
mine the role of these insights in modi-
fying care to minimize morbidity and 
mortality from squamous cell carci-
noma. Clinical epidemiology will need 
to evaluate the notion of individual-
ized health care in its specific applica-
tions. Although rapid advances on this 
front have been realized over the past 
10 years, there have yet to be substan-
tial, widespread modifications to the 
practice of medicine. Large-scale tri-
als demonstrating the effectiveness of 
prescribing based on genetic profiling 
on improving patient outcomes must 
measure its value. We must proceed, 
but with caution.
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